Elite Pharmaceuticals Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Elite Pharmaceuticals Inc 's ROA in the first quarter of 2026?
Elite Pharmaceuticals Inc achieved a return on average assets (ROA) of 43.26 % in its first quarter of 2026, this is above ELTP's average return on assets of 12.15%.
Elite Pharmaceuticals Inc assets over the 12 months ending in its first quarter of 2026 are valued at $131 million

Despite the company's net income deteriorating, Elite Pharmaceuticals Inc was able to improve its ROA compared to the fourth quarter of 2026.

However, within the Healthcare sector 25 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 113, from total ROA ranking in the fourth quarter of 2026 at 414.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Total Assets Change	33.34 %	69.55 %	16.74 %	35.06 %	29.36 %
Y / Y Net Income Change	-	8.61 %	-	-	-
Net Income (TTM) in million	57	45	43	14	-11
Return On Assets (TTM)	43.26 %	36.87 %	41.32 %	13.7 %	-11.51 %
ELTP's Total Ranking	# 113	# 414	# 3347	# 3057	# 4226
Total Assets (TTM) in million	148	162	96	117	111
Seq. Total Assets Change	-8.6 %	69.55 %	-18.3 %	5.31 %	16.23 %
Seq. Net Income Change	-67.98 %	-0.71 %	35.7 %	-	-

ELTP's 5 Years Annual ROA >> Back to ELTP Management Effectiveness >> Compare ELTP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 10
Sector	# 26
Overall	# 99

Return On Assets Statistics
High	Average	Low
156.78 %	12.15 %	-275.23 %
(Jun 30 2015)		(Mar 31 2014)

Financial Statements
Elite Pharmaceuticals Inc 's Assets	$ 148 million	ELTP's Balance sheet
Elite Pharmaceuticals Inc 's Income	$ 6 million	Quarterly ELTP's Income Statement
ELTP's Income by Division		See ELTP's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022
Y / Y Total Assets Change	69.55 %	16.74 %	98.65 %	15.89 %	36.11 %
Total Assets in million	162	96	82	41	36
Y / Y Net Income Change	-	-	464.56 %	-59.97 %	74.87 %
Net Income in million	45	-4	20	4	9
Annual Return On Assets	27.63 %	-4.5 %	24.51 %	8.62 %	24.96 %

ELTP's 5 Years Annual ROA >> Back to ELTP Management Effectiveness >> Compare ELTP ROA to its Competitors

Comment on ELTP's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 27.63 % compared to prior year, due to annual net income growth of % to $44.87 million, while value of Elite Pharmaceuticals Inc 's overall assets grew just by 69.55 % to $162.42 million, compared to $162.42 a year before.

More Return On Assets Ratios
ELTP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ELTP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ELTP's Competitors
Subscribers only: Roa for Elite Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ELTP's Customers

You may also want to know
ELTP's Roi	ELTP's Inventory Turnover Ratio	ELTP's Growth Rates	ELTP's Dividend Comparisons
	ELTP's Profitability Ratios	ELTP's Asset Turnover Ratio	ELTP's Dividend Growth
ELTP's Roe	ELTP's Valuation Ratios	ELTP's Financial Strength Ratios	ELTP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %

Date modified: 2026-09-12T06:10:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.